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Human immunodeficiency virus-1 (HIV-1) exploits a number
of host cellular factors for successful survival and propagation.
The viral protein Nef plays an important role in HIV-1 patho-
genesis by interacting with various cellular proteins. In the
present work, we identified Cyclin K (CycK) as a novel Nef-in-
teracting protein, and for the first time, we showed that CycK
inhibits HIV-1 gene expression and replication in a Nef-depen-
dent manner. The positive elongation factor b complex com-
prising cyclin-dependent kinase 9 (CDK9) and Cyclin T1 is a
critical cellular complex required for viral gene expression and
replication. Enhanced expression of CycK in the presence ofNef
induced CycK-CDK9 binding, which prevented CDK9-Cyclin
T1 complex formation and nuclear translocation of CDK9,
resulting in inhibition of HIV-1 long terminal repeat-driven
gene expression. Furthermore, this effect of CycK was not
observed with Nef-deleted virus, indicating the importance of
Nef in this phenomenon. Finally, silencing of CycK in HIV-1-
infected cells resulted in increased translocation of CDK9 into
the nucleus, leading to increased viral gene expression and rep-
lication. These data also suggest that endogenous CycK might
act as an inhibitory factor for HIV-1 gene expression and repli-
cation in T-cells. Thus, our results clearly demonstrate that
CycK utilizes HIV-1 Nef protein to displace CycT1 from the
positive elongation factor b complex, resulting in inhibition of
HIV-1 gene expression and replication.
Human immunodeficiency virus type-1 (HIV-1) perpetuates
its survival in the host by utilizing multiple strategies such as
irreversible integration of its DNA into the host cell genome
to establish the provirus (1), diversification of its genome to
escape or tolerate adaptive immune responses (2), and use of
the accessory genes (nef, vif, vpu, and vpr) to modulate host cell
immune responses further (3–5). These viral accessory genes
are frequently seen as dispensable in many in vitro cell culture
systems but seem to be indispensable, in the context of natural
infections in vivo. Among these accessory genes, pleiotropic
functions of Nef have been studied extensively. It is a 27–30-
kDa, N-terminally myristoylated protein having a well charac-
terized CD4 down-regulatory activity (6). Nef does not possess
any enzymatic activity, but it modulates diverse signaling path-
ways and the gene expression of host cell proteins (7, 8). Fur-
thermore, Nef influences the activation state of the host cell by
bringing together different host cell proteins, protein kinases,
and components of the endocytic machinery and making the
cells permissible to the virus (9, 10). All these functions of Nef
are manifested by a number of events such as activation of sig-
naling molecules, modulation of apoptosis, activation of tran-
scription factors, mitigation of transcriptional repressors, and
an increase in the infectivity of virions (11). Although these
functions of Nef have been well studied, controversy exists on
its role in viral infectivity and replication as both negative (12,
13) and positive (14, 15) roles have been attributed in the liter-
ature. Although a number of reports show that Nef increases
viral replication by activating T-cells, the molecular basis of
Nef-induced viral gene expression and replication remains to
be clearly elucidated. Nef was also shown to physically interact
with Tat and augment viral gene expression (16), although
availability of Tat is critical for the elongation step of long ter-
minal repeat (LTR)2-driven transcription by RNA polymerase
II. Several cellular factors have been identified for their roles in
this process, including positive transcription elongation factor
b (P-TEFb) complex. Different P-TEFb complexes isolated
from mammalian cells contain a common catalytic subunit,
cyclin-dependent kinase 9 (CDK9), and one of the regulatory
cyclins, CycT1, CycT2a, CycT2b, or CycK (17–19). However,
CycT1-containing P-TEFb complex is the key complex respon-
sible for HIV-1 transcription elongation (19). Tat is expressed
early in the replicative cycle ofHIV and is essential for viral gene
expression from the LTR promoter. It recognizes the 5-bulge
in the transactivation response stem loop RNA, which is
located at the 5-end of all viral transcripts. Tat binds to CycT1,
and together they form the combinatorial surface that interacts
with the transactivation response RNA with high affinity and
specificity. The obligate partner of CycT1, CDK9, then hyper-
phosphorylates the C-terminal domain (CTD) of RNA poly-
merase II, resulting in increased HIV-1 transcription elonga-
tion (20, 21).
HIV-1 gene expression is controlled by several cellular aswell
as viral proteins, including Nef. Evidences suggest that Nef
enhances Tat-mediated viral transcription through a heteroge-
neous nuclear ribonucleoprotein K-nucleated signaling com-
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plex (22). In another study, Hsp40 was shown to interact and
co-localize with Nef in the nucleus and thereby augment LTR-
driven gene expression (23). In contrast, HEXIM1 and Hsp70
negatively regulate HIV-1 gene expression and replication (24,
25). HEXIM1 along with 7SK RNA was shown to be essential
for inactivation of the P-TEFb complex (26, 27). Reportedly, the
HEXIM1–7SK RNA complex physically competes with Tat for
binding to P-TEFb (28). Recently, CycK has been also shown to
inhibit viral replication in a T-cell line by inhibiting LTR-medi-
ated transcription (29), although the mechanism of inhibition
remains to be elucidated. CycK was first identified as a protein
that could restore progression of the cell cycle and was most
closely related to humanCyclins C andH (30). The kinase part-
ner of CycK was identified as CDK9 (17), although a recent
report also indicates CycK interaction with CDK12 and -13
(31). The complex between CycK and CDK9 was also shown to
function as a CTD kinase in vitro (17).
Although Nef was earlier reported as a negative factor for
viral replication (32), recent evidence has convincingly demon-
strated Nef as an enhancer of viral replication (16, 22, 33–36).
Nef performs most of its functions by interacting with cellular
proteins. The majority of the functional studies of Nef to date
have been performed with HIV-1 subtype B Nef protein, and
there have been few studies using subtype CNef protein. In the
present study, we attempted to identify novel Nef-interacting
host cell proteins using subtype C Nef as a bait in a yeast two-
hybrid system.Our results show that bothHIV-1 subtypeC and
B Nef interact with human Cyclin K in vitro and in vivo. Fur-
thermore, CycK overexpression led to reduction in LTR-medi-
ated gene expression and virus replication in the presence of
Nef. Finally, CycK along with Nef disrupted CDK9-CycT1
interaction and thereby inhibited nuclear translocation of
CDK9, consequently inhibiting viral gene expression and
replication.
EXPERIMENTAL PROCEDURES
Plasmids, Cell Lines, and Antibodies—The nef gene from
HIV-1 subtype C Indian isolate IN301904 (37) was cloned into
pAS2-1 (Clontech) and pcDNA3.1 vector (Invitrogen), respec-
tively, as described earlier (23). The sequence of cloned nefwas
confirmed by DNA sequencing using an ABI 310 Genetic Ana-
lyzer (Applied Biosystems). Immunoblotting was used to con-
firm the expression of Nef from both vectors. The pAS2-1NefC
plasmid expressing subtype C Nef and Gal4 DNA binding
domain as a fusion protein was used as the bait in yeast two-
hybrid screening of a cDNA library of human leukocytes in the
pACT2 vector obtained from Clontech. The NL4-3 molecular
clone (pNL4-3) was obtained from the National Institutes of
Health AIDS Reagent Program (38). The nef-deleted NL4-3
molecular clone (pNL4-3Nef) and glutathione S-transferase
(GST)-Nef (B) plasmids were obtained from Dr. John C. Gau-
telli (39) and Dr. K. Saksela, respectively. The vectors express-
ing HA-Nef and HA-Nef mutants used in this study were
obtained from Dr. W. C. Greene (40). The subtype C Nef-ex-
pressing GST-Nef plasmid was constructed by cloning subtype
C nef gene into BamHI and EcoRI sites of pGEX-5X.1 (GE
Healthcare). The sequence of cloned nef was confirmed by
DNA sequencing as above and also by Western blotting with
Nef- and GST-specific antibodies. EGFP-Nef plasmid was con-
structed by cloning the complete GFP-Nef fusion gene
sequence from pEGFPN2-Nef in EcoRI and NotI sites of
pcDNA6HisC (Invitrogen). Cyclin K (CCNK) gene encoding
the 354-amino acid isoform (30) was cloned in-frame into
BamHI and EcoRI sites of pcDNA6HisC to obtain
pcDNA6HisC-Cyclin K (pc-CycK). The cloning of pc-CycK
was confirmed by restriction digestion and byDNA sequencing
in an ABI 310 Genetic Analyzer (Applied Biosystems). The
expression was confirmed by Western blotting using anti-
Xpress epitope and CycK antibodies. HEK-293T cells (human
embryonic kidney cell line) and Jurkat cells (CD4 human T
cell line) were obtained from the National Centre for Cell Sci-
ence Cell Repository in India. CEM-GFP, a CD4 human T cell
line, was obtained from the National Institutes of Health AIDS
repository. Jurkat-1G5 cells (CD4 human T cell line) having a
copy of integrated LTR-Luc in the genome were obtained from
the National Institutes of Health AIDS Reagent Program. Anti-
bodies specific for Cyclin K, Cyclin T1, CDK9, GAPDH, and
HA tag were obtained from Santa Cruz Biotechnology. Anti-
Nef monoclonal antibody was obtained from Fitzgerald, anti-
Nef polyclonal serum was obtained from Dr. Shahid Jameel,
International Centre for Genetic Engineering and Biotechnol-
ogy, New Delhi, India (41), and anti-p24 gag polyclonal serum
was obtained from the National Institutes of Health AIDS
repository.
Yeast Two-hybrid Screening—A human leukocyte cDNA
library in pACT2 vector (Clontech) was screened forNef-inter-
acting proteins by co-transformationwith the pAS2-1NefCbait
plasmid into yeast strain AH109 (Clontech) as described previ-
ously (23). Positive clones were selected based on growth in
medium lacking adenine, histidine, tryptophan, and leucine
and also by expression of -galactosidase. Co-transformants in
AH109 yeast strain were screened three times for growth on
these selection plates and also for -galactosidase activity to
exclude false positive clones. A liquid-galactosidase assay was
finally performed to confirm the interaction using the yeast
-galactosidase assay kit (Pierce) according to the manufactur-
er’s protocol. The interacting protein in the positive clone was
identified by rescuing the gene fragment using PCR amplifica-
tion with pACT2-specific primers followed by DNA sequenc-
ing and BLAST analysis.
HIV-1 Infection and Virus Quantitation—CEM-GFP cells
(2 106) were infected with HIV-1NL4-3 virus at a multiplicity
of infection of 0.5 in the presence of Polybrene (1 g/ml) as
described earlier (23). 24 h postinfection, cells were transfected
with 200 nM siRNA, and then 48 h later, cells were harvested
and lysed for preparation of whole cell lysate. The culture
supernatants from infected and molecular clone-transfected
cells were used to determine virus production by p24 gag anti-
gen capture ELISA (Perkin Elmer Life Sciences).
Transient Transfection and Luciferase Assay—HEK-293T
cells were transfected with HIV-1 LTR-reporter vector (pLTR-
Luc) along with other expression vectors using the calcium
phosphate precipitation method and were harvested 36 h post-
transfection for luciferase assay. Jurkat-1G5 cells were trans-
fected with pNL4-3 and pc-CycK using Lipofectamine 2000
(Invitrogen) according to themanufacturer’s protocol, and cells
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were harvested 48 h post-transfection for luciferase assay. The
cells were then lysed in cell lysis reagent (Promega), and lucif-
erase assays were performed using Luclite substrate (Perkin-
Elmer Life Sciences). Normalization of transfection efficiency
was done using enhanced green fluorescent protein reporter
(pEGFP-N1) co-transfection and quantitation as described ear-
lier (42). For RNAi experiments, Jurkat-1G5 cells were trans-
fected with 100 nM siRNAs along with expression vectors using
Lipofectamine 2000 (Invitrogen) according to the manufactur-
er’s protocol. The culture supernatants were also collected at
the time of luciferase assay fromHIV-1NL4-3molecular clone-
transfected cells to determine virus production.
GST Pulldown, Immunoprecipitation, and Immunoblott-
ing—Escherichia coli BL21(DE3) cells expressing either GST or
GST-Nef were induced with isopropyl -D-thiogalactoside fol-
lowed by purification of proteins using glutathione-Sepharose
beads (Amersham Biosciences). Jurkat cells were lysed in lysis
buffer (50mMTris-HCl, pH 7.4, 5mMEDTA, 0.12 MNaCl, 0.5%
Nonidet P-40, 0.5 mM NaF, 1 mM dithiothreitol, 0.5 mM phen-
ylmethylsulfonyl fluoride) with a protease inhibitor mixture
(Roche Applied Bioscience) on ice for 45 min. The clarified
lysates were incubated with either GST or GST-Nef protein
immobilized on glutathione-Sepharose beads at 4 °C and sub-
jected to five washes with lysis buffer. The complexes were
resuspended in Laemmli sample buffer, boiled, and resolved by
12% SDS-PAGE. Proteins were transferred onto polyvinylidene
difluoride (PVDF) membrane, and the membrane was probed
with anti-CycK antibody.
Infected and uninfected CEM-GFP cells and co-transfected
HEK-293T cells were lysed in lysis buffer as mentioned above.
The clarified lysate was incubated with polyclonal antibody,
and the antigen-antibody complexwas pulled down by an equal
mixture of ProteinA andGbeads followed by resolution by 12%
SDS-PAGE. The proteins were transferred onto PVDF mem-
brane, and then the membrane was probed with specific anti-
bodiesmentioned above. The blotswere developed by using the
ECL Plus system (Amersham Biosciences). Furthermore, equal
amounts of protein were taken from cell lysates and were
resolved by SDS-PAGE followed by immunoblotting for CycK
and other proteins.
ImmunofluorescenceMicroscopy—HEK-293T cells grown on
coverslips were co-transfected with expression vectors using
Lipofectamine (Invitrogen). Cells were harvested 24 h post-
transfection and stained with CycK and Nef antibodies after
fixing with 2% paraformaldehyde. The secondary antibodies
used were Cy3-conjugated, Cy5-conjugated, and fluorescein
isothiocyanate-conjugated specific antibodies (Chemicon).
After washing, cells were mounted in mounting medium con-
taining antifade reagent (Santa Cruz Biotechnology) on the
slide, and the samples were analyzed with a confocal micro-
scope (Zeiss LSM 510).
Reverse Transcription-PCR—RNAwas prepared fromHIV-1
NL4-3-infected and uninfected CEM-GFP cells or from Jurkat-
1G5 cells using TRIzol reagent (Invitrogen). The cDNA was
made using Moloney murine leukemia virus reverse transcrip-
tase (Invitrogen) followed by amplification by PCR for CCNK,
-ACTIN, and HIV-p24 gene with Taq polymerase (Bangalore
Genei) using standard conditions and gene-specific oligonu-
cleotide primers. The primers used were as follows: CCNK: for-
ward primer, 5-TGCAAAAGCAACTCAAAGGTG-3; re-
verse primer, 5-AACAAACGCTCCCACCCTC-3; -ACTIN:
forward primer, 5-ATCTACCCGTGTCACACCCACTGGGG-
CAGT-3; reverse primer, 5-GGAGGTAGCAGGTGGCGTT-
TACGAAGATC3; and HIV-p24: forward primer, 5-ATAA-
TCCACCTATCCCAGTAGGAGAAAT-3; reverse primer,
5-TTTGGTCCTTGTCTTATGTCCAGAATGC-3.
Preparation of Nuclear and Cytoplasmic Extracts—HIV-1-
infected CEM-GFP and transfected HEK-293T cells were
harvested and washed with ice-cold phosphate-buffered
saline (PBS). Nuclear and cytoplasmic extracts were pre-
pared using ProteoJET reagent (Fermentas) according to the
manufacturer’s protocol. Equal amounts of nuclear and
cytoplasmic extracts were used for immunoblotting.
Statistical Analysis—Each individual experiment was re-
peated at least three times. The error bars in the figures repre-
sent themean S.D. of three independent experiments. Statis-
tical analysis of the experimental data was performed using
Student’s t testwith the levels of significance defined as p 0.05
(*) and p 0.01 (**).
RESULTS
HIV-1 Nef protein interacts with a number of cellular pro-
teins, most of which perform critical functions in signaling
pathways. Although the role of Nef in HIV-1 pathogenesis has
beenwell studied, themolecularmechanismof howNef utilizes
these interacting cellular factors to modulate viral replication
and gene expression is still a conundrum. The functions attrib-
uted to Nef are believed to be conserved across various HIV-1
subtypes, and to date, the majority of the functional studies
have been performed with subtype B Nef protein. As subtype C
has become themost prevalent subtype in the world at present,
we wanted to identify novel cellular factors, if any, that may
interact with subtype C Nef protein. The subtype C Nef from
Indian isolate IN301904 (37) used in the yeast two-hybrid
screening was shown to have 84% similarity with subtype B
NL4-3 Nef (23).
Identification of Cyclin K as Subtype C Nef-interacting
Protein—To identify cellular factors interacting with subtype C
Nef, we performed a yeast-two hybrid screening of a human
leukocyte cDNA library using full-length subtype CNef as bait.
Positive clones were identified after several rounds of screening
and culture on X-gal-containing dropout plates (Fig. 1A). The
gene expressed in the positive clonewas amplified by PCRusing
pACT2-specific primers followed by DNA sequencing. Se-
quence analysis and database comparison revealed that the
clone expressed a gene encoding for Cyclin K (GenBankTM
Gene ID: 8812). To validate this interaction, a liquid -galacto-
sidase assay was performed, and the clone expressing Cyclin
K and Nef showed -galactosidase activity comparable with
the positive control (Fig. 1B). To further confirm our finding,
a GST-Nef (subtype C) pulldown assay was performed using
Jurkat cell lysate as described under “Experimental Proce-
dures.” The result of the pulldown clearly indicates that
Cyclin K (CycK) interacts with subtype C Nef but not with
GST (Fig. 1C). To see whether these proteins interact in vivo,
immunofluorescence staining was performed in subtype C
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Nef-transfected 293T cells. Interestingly, these proteins co-
localized primarily in the cytoplasm with some localization
in the nucleus (Fig. 1D).
Cyclin K Also Interacts with Subtype B Nef Both in Vitro and
in Vivo—To test whether CycK also interacts with subtype B
Nef, a GST pulldown assay was performed as described above.
Jurkat cell lysate was incubated with bead-bound GST and
GST-Nef (subtype B) followed by immunoblotting with Cyclin
K antibody, which showed that CycK specifically interacts with
GST-Nef but not with GST alone (Fig. 1E). Immunofluores-
cence stainingwas also performed in pNL4-3- andpc-CycK-co-
transfected HEK-293T cells to confirm in vivo interaction of
CycK with Subtype B Nef. Both proteins were found to be co-
localized extensively in the cytoplasm as shown in Fig. 1F. We
further validated this interaction in vivo by co-immunoprecipi-
tation from uninfected and HIV-1NL4-3-infected CEM-GFP
cells. Uninfected and HIV-1-infected cell lysates were immu-
noprecipitatedwith eitherNef orCyclinK antibody followed by
immunoblotting with CycK or Nef antibody. The analyses of
immunoprecipitates clearly suggest that CycK and Nef specifi-
cally interact in HIV-1-infected cells (Fig. 1G). The uninfected
cell lysate served as a control in co-immunoprecipitation exper-
iments. These results clearly suggest that Nef interacts with
Cyclin K both in vitro and in vivo.
Cyclin K Inhibits HIV-1 LTR-driven Gene Expression in Pres-
ence ofNef—CyclinKwas first identified as a novel C type cyclin
that is associated with an in vitro kinase activity toward CTD of
RNA polymerase II (30). As this activity is important for HIV-1
gene expression, we wanted to examine the effect of CycK on
HIV-1 LTR-driven viral gene expression. First, HEK-293T cells
were co-transfected with the pLTR-Luc construct along with
Tat and CycK expression vectors. As shown in Fig. 2A, overex-
pression of CycK in the presence of Tat alone did not cause any
significant change in LTR-driven reporter activity. However, in
the presence ofNef, CyclinKoverexpression led to inhibition of
both Tat- and Nef-induced LTR-driven gene expression in
293T cells in dose-dependent manner (Fig. 2B). This result
clearly shows that CycK inhibits HIV-1 LTR-driven gene
expression in the presence of Nef. To explore this finding fur-
ther, we then used Jurkat-1G5 cells, a human CD4 reporter
T-cell line having a copy of “integrated” LTR-Luc in the genome
(43). Jurkat-1G5 cellswere transfectedwith increasing amounts
of CycK along with an HIV-1 molecular clone (pNL4-3) fol-
lowed by a luciferase activity assay 48 h post-transfection.
There was a significant reduction in luciferase activity upon
CycK overexpression in a dose-dependent manner (Fig. 2C).
Concurrently, Western blotting indicated that p24 expression
in these cells was also reduced in a dose-dependent manner
with increasing expression of CycK (data not shown). To fur-
ther elucidate the effect of CycK on viral gene expression and
replication, a p24 antigen capture ELISA of culture supernatant
of these cells was also performed. Virus production in Cyclin
K-overexpressing cells analyzed by p24 antigen release in the
culture supernatant was significantly reduced in a dose-depen-
dent manner as compared with pNL4-3 only-transfected cells
(Fig. 2D, gray bars). Moreover, when Jurkat-1G5 cells were
FIGURE 1. Cyclin K physically interacts with HIV-1 Nef protein. A, Cyclin K interacts with HIV-1 subtype C Nef in the yeast two-hybrid assay. A human
leukocyte cDNA library was screened using subtype C Nef as bait in the yeast two-hybrid system. One of the clones co-expressing Cyclin K and Nef was found
to be positive after repeated screening and was grown on a quadruple knock-out plate with appropriate controls. B, -galactosidase activity of Cyclin K-Nef
yeast co-transformant in liquid -galactosidase activity assay as described in the text. C, GST-Nef (subtype C) pulls down Cyclin K from Jurkat lysate. GST and
GST-Nef (subtype C) were incubated with Jurkat cell lysate followed by SDS-PAGE and immunoblotting with CycK antibody. D, co-localization of Cyclin K and
subtypeCNef in co-transfectedHEK-293T cells. HEK-293T cellsweregrownoncoverslips and transfectedwithpcDNA-NefCandpc-CycK.After 24h, transfected
cells were stained with Nef and Cyclin K antibodies as described in the text. The immunofluorescence was visualized by confocal microscopy. E, GST-Nef
(subtype B) also pulls down Cyclin K from Jurkat lysate. GST and GST-Nef (subtype B) were incubated with Jurkat cell lysate followed by SDS-PAGE and
immunoblottingwithCycK antibody. F, co-localization of Cyclin K and subtypeBNef in co-transfectedHEK-293T cells. HEK-293T cellswere grownon coverslips
and transfected with pNL4-3 and pc-CycK. The immunofluorescence staining and visualization were performed as described above. G, Nef and CycK interact
in HIV-1-infected CEM-GFP cells. CEM-GFP cells were infected with HIV-1NL4-3 virus as described in the text. The cells were lysed on day 5 postinfection. The
lysates of uninfected (U) and infected (I) CEM-GFP cells were co-immunoprecipitated (IP) with either Nef or CycK antibody followed by immunoblotting with
CycK or Nef antibody, respectively, as presented in the figure. NEG, negative; POS, positive. The red lines in panels D and F indicate 10 m scale.
Cyclin K Inhibits HIV-1 Gene Expression and Replication
22946 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286•NUMBER 26•JULY 1, 2011
 by guest on January 20, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
transfected with a Nef-deleted molecular clone (pNL4-3Nef),
CycK-mediated reduction in virus production was not ob-
served at all (Fig. 2D, black bars). These data clearly suggest that
Cyclin K acts as a cellular inhibitory factor against HIV-1 by
reducing viral gene expression and replication in a Nef-depen-
dent manner.
Endogenous Cyclin K Reduces Viral Gene Expression and
Replication in T-cells—To identify the role of endogenous
CycK in HIV-1 gene expression and replication, Jurkat-1G5
cells were co-transfected with pNL4-3 and specific siRNA to
silenceCycK expression as described under “Experimental Pro-
cedures.” After 72 h of transfection, cells were harvested, and
culture supernatants were collected for estimation of virus pro-
duction by a p24 antigen capture ELISA. The harvested cells
were used for cell lysate preparation. The efficacy of siRNAwas
checked by immunoblotting, and the cell lysate was also used
for a luciferase activity assay. As compared with control
siRNA-transfected Jurkat-1G5 cells, transfection of CycK
siRNA showed significant silencing of CycK expression (Fig.
3A, inset). The luciferase activity in CycK siRNA-transfected
cells was significantly increased as compared with the con-
trol siRNA-transfected cells (Fig. 3A). The viral expression
was also checked by immunoblotting for p24 gag protein.
The expression level of p24 was higher in CycK siRNA-
transfected cells as compared with control (Fig. 3A, inset).
Furthermore, a similar result was obtained when virus pro-
duction from siRNA-transfected cells was determined by a
p24 antigen capture ELISA. The amount of virus in the cul-
ture supernatant of CycK siRNA-transfected cells was sig-
nificantly increased as compared with control siRNA-
transfected cells (Fig. 3B). These results clearly indicate that
CycK down-regulation leads to an increase in HIV-1 gene
expression and virus production.
To assess the role of Cyclin K in a more physiological
scenario, we then performed the above experiment in an
HIV-1-infected CEM-GFP reporter T-cell line. The CEM-
GFP cells were first transfected with siRNA, and after 24 h,
they were infected with HIV-1NL4-3 at 0.5 multiplicity of
infection. On day 3 postinfection, cells were harvested to
monitor progression of infection by flow cytometry. The
cells transfected with CycK siRNA showed a higher number
of GFP-positive cells, indicating increased infection, as
compared with control siRNA-transfected cells (data not
shown). Analysis of the virus present in culture supernatant
by a p24 antigen capture ELISA showed significantly more
virus production by CycK siRNA-transfected cells as com-
FIGURE 2. Cyclin K inhibits HIV-1 LTR-driven gene expression and replication in Nef-dependent manner. A, Cyclin K does not modulate LTR-driven
luciferase expression in the presence of Tat alone. HEK-293T cells were transfected with HIV-1 LTR-Luc reporter vector along with pc-CycK in increasing
amounts (0.3–1.2 g) and with pcDNA-Tat (0.25 g) followed by a luciferase assay 36 h post-transfection. The total amount of DNA transfected was
equal in all lanes. B, Cyclin K down-regulates Tat-induced LTR-driven luciferase expression in the presence of Nef. HEK-293T cells were transfected with
HIV-1 LTR-Luc reporter vector along with pc-CycK in increasing amounts (0.3–1.2 g) and with pcDNA-Nef (0.5 g) and pcDNA-Tat (0.25 g). 36 h
post-transfection, cells were lysed in Promega cell lysis reagent, and a luciferase assay was performed. C, Cyclin K inhibits integrated LTR-driven gene
expression in T-cells. Jurkat-1G5 cells were transfectedwith pNL4-3 (1g) and increasing amounts of pc-CycK (0.25–0.5g). 48 h post-transfection, cells
were lysed in Promega cell lysis reagent followed by a luciferase assay. D, Nef is necessary for Cyclin K-mediated inhibition of HIV-1 replication.
Jurkat-1G5 cells were transfected with either pNL4-3 (gray bars) or pNL4-3Nef (black bars) and with increasing amounts of pc-CycK (0.25–0.5 g) as
presented in the figure. 48 h post-transfection, the culture supernatant was collected, and the amount of virus present in the culture supernatant was
estimated by a p24 gag antigen capture ELISA.
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pared with the control siRNA-transfected cells (Fig. 3C). A
similar pattern was obtained by immunoblotting for p24
(Fig. 3C, inset), thereby indicating that CycK acts as an inhib-
itory factor in HIV-1-infected cells.
Cyclin Box 1 Is Required for CycK-mediated Reduction of
LTR-driven Gene Expression—Human CycK is a 354-amino
acid protein; however, a less abundant isoform of CycK consist-
ing of 580 amino acids also exists. The overall structure of CycK
FIGURE 3. Cyclin K silencing increases LTR-mediated gene expression and virus production in T-cells. A, inhibition of Cyclin K expression by siRNA
leads to an increase in LTR-driven luciferase activity in Jurkat-1G5 cells. Jurkat-1G5 cells were transfected with 100 nM control (siCtrl) siRNA or CycK-
specific siRNA (siCycK), and 24 h post-transfection, cells were transfected with pNL4-3 vector (1 g). 48 h post-transfection, cells were harvested, and a
luciferase assay was performed. The inset shows the efficiency of siRNA-mediated Cyclin K silencing by immunoblotting. B, inhibition of Cyclin K
expression by siRNA leads to an increase in virus production from Jurkat-1G5 cells. The virus released in the culture supernatant of cells in the
experiment described in A was estimated by a p24 gag antigen capture ELISA. C, Cyclin K silencing increases virus production in HIV-1NL4-3-infected
CEM-GFP cells. CEM-GFP cells were first transfectedwith 200 nM control or CycK-specific siRNA. 24 h post-transfection, cells were infectedwith HIV-1NL4-3
at 0.5 multiplicity of infection, and on day 3, the culture supernatant was used for a p24 antigen capture ELISA. The inset shows the efficacy of
siRNA-mediated silencing by immunoblotting. GDH, Glyceraldehyde-3-phosphate dehydrogenase loading control.
FIGURE4.Cyclinbox1domainofCyclinK isnecessary for its inhibitoryactivityonLTR-drivengeneexpressionandHIV-1virusproduction.A, schematic
representation of Cyclin Kmutants generated and used in the present study. B, cyclin box 1 domain is required for the inhibition of HIV-1 LTR-driven luciferase
activity. HEK-293T cells were transfectedwith LTR-Luc reporter and pNL4-3molecular clone alongwith various CycKmutant expression vectors as indicated in
the figure. 24 h post-transfection, cells were harvested followed by a luciferase assay of the lysate. C, cyclin box 1 domain is required for the inhibition of HIV-1
virus production. HEK-293T cells were transfected with LTR-Luc reporter and pNL4-3 molecular clone along with various CycK mutant expression vectors as
indicated in the figure. 24 h post-transfection, cell supernatants were used to analyze the virus production by a p24 antigen capture ELISA. D, expression of
different Cyclin Kmutant proteins in transfected HEK-293T cells. HEK-293T cell lysates were examined for the expression of various CycKmutants using Xpress
epitope antibody and GAPDH by Western blot analysis in the experiments in B and C.
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is similar to other cyclin structures. It consists of 10 helical
domains, which are arranged in two cyclin boxes alongwith two
short helices (HNa and HNb) preceding the N-terminal cyclin
box. The five helices comprising the N- and C-terminal cyclin
domains are designated as H1–H5 and H1–H5, respectively.
The N-terminal domain (amino acids 1–151) of CycK is
responsible for binding to CDK9; however, the two N-terminal
helices HNa and HNb are not essential (44). The region from
amino acids 152 to 267 forms cyclin box 2, and the region com-
prising amino acids 268–354 can be considered as the C termi-
nus of the protein (Fig. 4A). Different deletion mutants of
Cyclin K, as shown in Fig. 4A, were cloned in pcDNA6HisC.
To investigate the effect of different CycK mutants on LTR-
mediated gene expression, HEK-293T cells were transfected
with pLTR-Luc reporter plasmid along with pNL4-3 and wild
type or different CycKmutants followed by a luciferase activity
assay. Upon wild type CycK overexpression (Fig. 4B, third bar),
the luciferase activitywas reduced by5-fold as comparedwith
that of vector control (second bar). A similar pattern was
observed when CycK(1–267) (fourth bar) and CycK(1–151)
(sixth bar)mutantswere used in the experiment (Fig. 4B). How-
ever, no significant change in luciferase activity was observed
when cyclin box 1 deletion mutants like CycK(152–354),
CycK(152–267), and CycK(268–354) were co-transfected with
LTR-Luc and pNL4-3 vectors (Fig. 4B), indicating that the
N-terminal end of Cyclin K was important for CycK activity,
whereas the C-terminal end was not required for this activity.
The amount of virus produced in culture supernatant of these
transfected cells was also estimated, and a similar pattern was
observed, indicating that amino acids 1–151 of CycK were
important for CycK-mediated reduction in virus production
(Fig. 4C). These results suggest that cyclin box 1 is responsible
for the inhibitory activity of Cyclin K. The expression levels of
Cyclin K wild type and the mutants in the above experiment
were confirmed by immunoblotting with anti-Xpress epitope
antibody (Fig. 4D).
Domains/Motifs Responsible for CycK-Nef Interaction—To
find the region of Cyclin K important for interaction with Nef,
immunoprecipitation of wild type or CycK mutants and
Nef-transfectedHEK-293T cell lysate was performedwith anti-
Nef antibody followed by immunoblotting of the complex with
anti-Xpress epitope antibody. Our results clearly show that Nef
specifically interacts with only wild type CycK and the two
mutants having the region comprising amino acids 1–151 (Fig.
5A). These data suggest that domain 1–151 is responsible for
the Nef binding property of CycK, which correlates well with
the inhibitory activity of CycK delineated in the earlier figure
(Fig. 4C). It has been reported that Nef has some signature
motifs responsible for binding to various cellular proteins (45).
To explore the motif of Nef important for binding to CycK, we
used a set of Nef point mutants (40). HEK-293T cells were co-
transfected with HA-Nef mutant expression vectors along with
CycK-WT expression vector. The cell lysates were then sub-
jected to immunoprecipitationwith CycK antibody followed by
immunoblotting with Nef antibody. The co-immunoprecipita-
tion analysis indicates that myristoylation of Nef is required for
CycK interaction as complete loss of interaction was observed
when the glycine at the second position, which is critical for
myristoylation, was replaced with alanine in Nef (Nef-G2A
mutant) (Fig. 5B).
FIGURE 5.Mutational analysis of CycK-Nef interaction. A, cyclin box 1 of Cyclin K is important for its interaction with Nef. HEK-293T cells were transfected
with HA-Nef expression vector along with various CycK mutant vectors as indicated in the figure. 24 h post-transfection, immunoprecipitation (IP) was
performedwithNef antibody followedbyWestern blotting (WB) with Xpress tag antibody for Cyclin K. The right side shows a schematic representation of CycK
mutants and the results of their interaction with HIV-1 Nef protein. The lower panels show the immunoblotting of input samples. B, G2Amutation in Nef leads
to abrogation of Nef-Cyclin K interaction. HEK-293T cells were transfected with HA-Nef mutant expression vector along with CycK vector as indicated in the
figure. 24 h post-transfection, immunoprecipitation was performed with Cyclin K antibody followed by Western blot analysis with Nef antibody. The lower
panel shows the immunoblotting of input samples.
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Nef Induces Cyclin K Interaction with CDK9—The CDK9-
CycT1 complex (P-TEFb complex) plays a central role inHIV-1
LTR-driven gene expression (46). Both CycK and CycT1 are
known to bind CDK9 through their N-terminal cyclin box of
which 53 of 80 residues are identical (17, 44). Based on this
report, we initiated studies to elucidate the mechanism of
CycK-mediated reduction in viral gene expression. To test
whether the presence of CycK alters the physical association
between CycT1 and CDK9, we performed a co-immunopre-
cipitation experiment by transfecting pNL4-3 along with
increasing amounts of CycK expression vector. The co-immu-
noprecipitation experiment revealed that in the presence of
increasing levels of CycK in pNL4-3-transfected cells CycK
interaction with CDK9 was increased, whereas CycT1 associa-
tion with CDK9was reduced in a dose-dependent manner (Fig.
6A). This result suggests that the increase in CycK levels in the
cell reduces the formation of the CDK9-CycT1 complex, which
is an active protein complex required for HIV-1 LTR-driven
gene expression.
To demonstrate the role of Nef in the context of CycK-me-
diated inhibition of CycT1-CDK9 interaction, we tested
whether the presence of Nef is essential for this CycK function.
We performed a co-immunoprecipitation experiment with
wild type and a Nef-deleted NL4-3 molecular clone (pNL4-
3Nef). Our results clearly show that CycK overexpression
leads to inhibition of CycT1-CDK9 interaction only in the pres-
ence of Nef, and there was no significant change in CycT1-
CDK9 interaction in the cells transfected with Nef-deleted
molecular clone (Fig. 6B). Thus, our co-immunoprecipitation
experiments indicate that CycK associates with CDK9 in the
presence of Nef and thereby prevents association of CDK9with
CycT1. We further validated this finding by performing a GST
pulldown assay using bead-bound GST-CycK to pull down
CDK9 from pNL4-3- and pNL4-3Nef-transfected HEK-293T
cell lysate. Western blot analysis of the GST-CycK pulldown
complex clearly indicates that in the presence of Nef CDK9
pulldown was significantly greater as compared with that in
the absence of Nef (Fig. 6C). All these results clearly suggest
that CycK physically interacts with CDK9 in the presence of
Nef, and this interaction prevents CDK9-CycT1 complex
formation.
Cyclin K Binding to CDK9 Inhibits Its Nuclear Translocation
in Presence of Nef—Previous studies have indicated that CDK9
shuttles between the nucleus and cytoplasm, and enhanced
expression of CycT1 increases CDK9 nuclear translocation,
suggesting a role for CycT1 in transporting CDK9 into the
nucleus (47). The localization of CycK has not been studied in
detail. However, when the sequences of CDK9, CycK, and
CycT1 were analyzed to predict the presence of a nuclear local-
ization signal, we found that only CycT1 has a nuclear localiza-
tion signal sequence. So based on the above information, we
hypothesized that inhibition of CDK9-CycT1 complex forma-
tion by CycK could be responsible for restricting CDK9 from
translocating into the nucleus to form active P-TEFb complex
and thus causing reduction in viral gene expression. We there-
fore analyzed whether ectopic expression of CycK inhibits
CDK9 nuclear translocation. We performed Western analysis
of nuclear and cytoplasmic extracts of HEK-293T cells trans-
fected with Nef and different amounts of CycK. It was clearly
evident that the presence ofNef andCycK significantly reduced
CDK9 translocation into the nucleus as analyzed by immuno-
blotting (Fig. 7A). This experiment also showed that with
increasing CycK expression there was a substantial decrease in
CDK9 levels in the nucleus (Fig. 7A). To further substantiate
this finding, we transfected HEK-293T cells with EGFP-Nef
and CycK expression vectors to perform an immunofluores-
cence study. In EGFP-Nef-transfected cells, CDK9 was evi-
dently co-localized in the cytoplasm with CycK and EGFP-Nef
(Fig. 7B). When EGFP alone was used as a control, CDK9 was
visiblemostly in the nucleus. Thus, the CycK-Nef complexmay
act as an inhibitory complex, which may restrict viral replica-
tion by binding to CDK9 and sequestering it in the cytoplasm.
To further confirm the above mentioned finding, we directly
examined the localization of CDK9 in pNL4-3- and pNL4-
3Nef-transfected cells in the presence of CycK by immunoflu-
orescence. Cells were counted, and the percentage of cells with
CDK9 localized in the cytoplasm andnucleuswas calculated for
three independent experiments. The results presented in Fig.
7C clearly show that CDK9was localizedmore in the nucleus of
pNL4-3Nef-transfected cells as compared with pNL4-3-
transfected cells. Representative immunofluorescence data are
shown in Fig. 7D. Put together, all these results clearly indicate
FIGURE 6. Cyclin K overexpression leads to increased binding with CDK9
and inhibition of CDK9-Cyclin T1 interaction in Nef-dependent manner.
A, Cyclin K binds to CDK9 and inhibits CDK9-Cyclin T1 interaction in pNL4-3-
transfected cells. HEK-293T cells were co-transfected with pNL4-3 and CycK
expression vector as shown in the figure. 200 g of lysate was immunopre-
cipitated (IP) with CDK9 antibody followed by immunoblotting with CycT1,
CycK, andCDK9 antibodies. B, Cyclin K inhibits CDK9-Cyclin T1 interaction in a
Nef-dependent manner. HEK-293T cells were transfected with pNL4-3 or
pNL4-3Nef along with pc-CycK. 150 g of cell lysate was immunoprecipi-
tatedwith CDK9 antibody followedby immunoblottingwith CycT1 antibody.
C, Cyclin K binding to CDK9 is increased in the presence of Nef. HEK-293T cells
were transfectedwith pNL4-3 or pNL4-3Nef. 150gof lysatewas incubated
with an equal amount of bead-bound GST and GST-CycK protein for a GST
pulldown assay as described in the text. The pulldown was detected by
immunoblotting with Nef and CDK9 antibodies.
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that CycK inhibits nuclear translocation of CDK9 in the pres-
ence of Nef.
Endogenous Cyclin K Restricts CDK9 Nuclear Translocation
in HIV-1-infected Cells—For further confirmation of the above
findings, we then investigated the localization of CDK9 inHIV-
1-infected T-cells in which Cyclin K expression was silenced.
We made nuclear and cytoplasmic extracts of CycK-silenced
and HIV-1-infected CEM-GFP cells and performed immuno-
blotting. The infected CEM-GFP cells that were transfected
with CycK-specific siRNA had more CDK9 in the nucleus as
compared with control siRNA-transfected cells (Fig. 8A).
Simultaneously, we checked for virus production in the culture
supernatant of these cells by a p24 antigen capture ELISA, and
as shown in Fig. 8B, the virus produced from CycK-silenced
infected cells was significantly increased as comparedwith con-
trol siRNA-transfected cells. These data clearly suggest that
CycK in the presence of Nef restricts viral gene expression and
replication by binding to CDK9 and inhibiting its translocation
into the nucleus. The inhibition of nuclear translocation of
CDK9 seems to prevent formation of active P-TEFb complex
necessary for HIV-1 LTR-driven gene expression and
replication.
DISCUSSION
The dependence of HIV-1 on host cellular factors is well
established. The multifunctional protein Nef is capable of
imparting extensive aid for HIV-1 pathogenesis by making a
niche in the form of an interactome. The Nef interactome con-
sists of multiple branches leading to critical cellular functions
like receptor down-modulation, cell signaling, cell migration,
apoptosis, and transcription regulation. To date, Nef has been
shown to interact with several important cellular factors, and
new proteins are being added frequently, unraveling its novel
functions. In the present study, we show for the first time that
FIGURE 7. Cyclin K restricts CDK9 nuclear translocation in presence of Nef. A, Cyclin K and Nef overexpression restricts CDK9 from nuclear translocation.
HEK-293T cells were co-transfectedwith increasing amounts of pc-CycKwith or without HA-Nef expression vector as indicated in the figure. Equal amounts of
nuclear (Nuc. Ext) andcytoplasmic extracts (Cyt. Ext)wereused for immunoblottingwithCDK9,CycT1, andNef antibodies asdescribed in the text. The sameblot
was probed for Lamin A/C and GAPDH to serve as loading controls. B, Cyclin K and Nef overexpression inhibits CDK9 nuclear translocation as visualized by
immunofluorescence. HEK-293T cells were grown on a coverslip and co-transfected with pc-CycK and EGFP-Nef or EGFP control vectors. After 24 h, cells were
stained for CycK and CDK9 as described in the text. Cells were thenmounted onto a glass slide and visualized by a confocal microscope. C, CDK9 translocation
into the nucleus is increased in the cells transfectedwith theNef-deletedmolecular clone. HEK-293T cellswere grownon a coverslip andwere transfectedwith
pNL4-3or pNL4-3Nef alongwithpc-CycK. Immunofluorescence stainingwasperformedwithCDK9andCycKantibodies. Cells stained for CDK9 in thenucleus
or cytoplasm were counted and plotted as a bar diagram with data from three independent experiments. Black and gray bars indicate CDK9-stained cells
transfected with pNL4-3 and pNL4-3Nef, respectively.D, representative immunofluorescence images of CDK9 localization in the experiment described in C.
Left and right panels are immunofluorescence images of cells transfected with pNL4-3 and pNL4-3Nef alongwith pc-CycK, respectively. BF, bright field;ve,
positive.
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HIV-1 Nef interacts with Cyclin K, which was identified by
yeast two-hybrid screening and was further confirmed by
immunoprecipitation and co-localization studies. This interac-
tion is not subtype-specific as both subtypes B andCNef bind to
CycK. Our data seem to corroborate previous reports (48), sug-
gesting that despite significant sequence differences in the Nef
gene from various subtypes functional properties remain rela-
tively well conserved.
CycK was first identified as a protein that could restore pro-
gression through the cell cycle and was most closely related to
human cyclins C and H (30). The kinase partner of CycK was
identified as CDK9 and was reported to function as a CTD
kinase in vitro (17). Recently Cyclin K was also shown to inter-
act with CDK12 and -13 (31), but its functional implication
remains to be clearly elucidated. CycT1 on the other hand is an
obligate cyclin partner of CDK9, and this complex (P-TEFb)
plays a key role in HIV-1 gene expression (19). As both CycK
and CycT1 bind to CDK9, it was reasonable to speculate a pos-
sible role of Nef-CycK interaction in HIV-1 LTR-driven gene
expression. Our results clearly show that CycK reduces LTR-
driven gene expression in a dose-dependent manner. More-
over, CycKwas able to reduce LTR activity only in the presence
of Nef, which suggests an apparent role of Nef-CycK interac-
tion in this phenomenon. Furthermore, CycK ectopic expres-
sion in Jurkat-1G5 cells was able to reduce LTR-mediated gene
expression and thus virus production. Additionally, when
endogenous CycK was knocked down using specific siRNA,
the viral gene expression was enhanced, and virus particle
release was also augmented in Jurkat-1G5 cells. Hence, our
findings convincingly indicate that CycK might possess an
HIV restricting property and that it is not a cell type-depen-
dent phenomenon.
Endogenous CycK seems to substantially reduce HIV-1 gene
expression and virus production as was evident in RNAi exper-
iments performedwithHIV-1NL4-3-infectedCEM-GFP cells. In
a report in 2008, Urano et al. (29) demonstrated that CycK
overexpression leads to reduction in HIV-1 production from
T-cell lines; however, the mechanism behind CycK-mediated
FIGURE 8. Cyclin K silencing leads to increased CDK9 nuclear transloca-
tion and virus production in HIV-1-infected CEM-GFP T-cells. A, Cyclin K
down-regulation leads to increased CDK9 translocation into the nucleus of
HIV-1-infected T cells. CEM-GFP cells were transfected with 200 nM control
(siCtrl) and CycK-specific siRNA (siCycK). 24 h post-transfection, cells were
infected with HIV-1NL4-3 at 0.5 multiplicity of infection; on day 3, cells were
harvested; and nuclear and cytoplasmic fractions were prepared as men-
tioned under “Experimental Procedures.” Equal amounts of extracts were
used for immunoblotting with CDK9, CycT1, CycK, and Nef antibodies.
GAPDH and Lamin A/C were used as loading controls. B, Cyclin K down-reg-
ulation leads to increased virus production from HIV-1-infected T-cells. The
amount of virus present in the culture supernatant of the cells described in A
was estimated by a p24 antigen capture ELISA. Nuc. Ext, nuclear extract; Cyt.
Ext, cytoplasmic extract; scr, scrambled.
FIGURE 9. Proposedmechanistic model for Cyclin K-mediated inhibition of HIV-1 gene expression and replication. The results obtained in the present
study indicate that in the presence of the Nef-Cyclin K complex CDK9-CycT1 interaction is abrogated, causing a reduction in active P-TEFb complex in the
nucleus and resulting in inhibition of HIV-1 LTR-driven gene expression and replication. However, in the absence of the Nef-Cyclin K complex, CDK9 is free to
bind to CycT1 and translocate into the nucleus, consequently leading to enhanced viral gene expression and replication.
Cyclin K Inhibits HIV-1 Gene Expression and Replication
22952 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286•NUMBER 26•JULY 1, 2011
 by guest on January 20, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
reduction of HIV-1 gene expression remained unexplored. Our
co-immunoprecipitation experiment along with immunofluo-
rescence studies confirmed that CycK not only binds to CDK9
in the presence of Nef but also reduces binding of CycT1 to
CDK9 and thereby restricts CDK9 translocation into the
nucleus. It is worth mentioning here that our mutational stud-
ies indicate CycK binding to only myristoylated Nef. Thus, it
might be hypothesized that membrane-associated Nef-CycK
complex only interacts with CDK9 and thereby restricts it from
translocating into the nucleus.Moreover, immunofluorescence
studies with wild type and a nef-deleted HIV-1molecular clone
demonstrated that Nef is essential for CycK-mediated restric-
tion of CDK9 nuclear translocation. Furthermore, immuno-
blotting analyses of nuclear and cytoplasmic extracts of CycK-
specific siRNA-treatedHIV-1-infected CEM-GFP cells showed
increased translocation ofCDK9 into the nucleus and increased
virus production.
Although CDK9-CycK forms an active kinase complex that
possesses CTD phosphorylating activity in vitro (17), its role in
HIV-1 transcription has not been studied. CycK and CycT1
have 53 identical residues in the cyclin homology box domain,
which is responsible for binding to CDK9 (44); hence, the pos-
sibility of competition between CycK and CycT1 for binding to
CDK9 cannot be ruled out. The Tat-interacting region, also
known as the Tat-responsive motif, located outside the cyclin
homology box of CycT1, is not present in CycK (49, 50), and
thus a possible role of the CDK9-CycK complex in modulating
HIV-1 transcription can be ruled out. To function as a part of an
active P-TEFb complex for HIV-1 gene transcription, CDK9
needs to be translocated into the nucleus, and it shuttles
between the nucleus and cytoplasm under the influence of
CycT1 levels in the cell (47). However, if CDK9 is restricted in
the cytoplasm, the amount of active P-TEFb complex in the
nucleus will be reduced, leading to inhibition of transcription.
The present work in the context of Nef-CycK interaction has
shown convincingly that CDK9 binding to CycK increases in
the presence of Nef, thereby reducing its binding to the obligate
partner CycT1. Hence, it may be hypothesized that binding to
Nef is responsible for the increased affinity of CycK toward
CDK9.
Thus, the present study provides insight into the molecular
mechanismofCycK-mediated reduction inHIV-1 gene expres-
sion and replication. In summary, we conclude that Nef inter-
acts with CycK, and the resulting complex leads to reduction in
HIV-1 LTR-driven gene expression by interfering with CDK9
binding to CycT1 and its translocation into the nucleus. Our
data also indicate that CycK function is not cell type-specific,
and endogenous CycK is capable of reducing viral gene expres-
sion. Finally, our results also suggest that Nef-CycK interaction
leads to reduction in the formation of active P-TEFb complex,
consequently inhibiting HIV-1 LTR-driven viral gene expres-
sion and replication. Based upon our findings, we propose a
model depicting how Nef-Cyclin K interaction leads to restric-
tion of CDK9 in the cytoplasm, thereby reducing the formation
of active CDK9-CycT1 complex and consequently reducing
HIV-1 gene expression and virus production (Fig. 9). It is inter-
esting to note that a recent report finds that CycK along with
CDK9 binds to checkpoint proteins and thus plays an impor-
tant role in replication-induced stress (51). Finally, identifica-
tion of CycK as a novel Nef-interacting host factor and the
consequences of this interaction provide another example for
utilization of a viral protein by the host in combating the
pathogen.
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